
|Videos|November 1, 2017 (Updated: October 7, 2020)
Dr. Chan Discusses Cabozantinib for the Treatment of NETs
Author(s)Jennifer Chan MD, MPH
Jennifer Chan, MD, MPH, clinical director, Program in Carcinoid and Neuroendocrine Tumors, Dana-Farber Cancer Institute, discusses a study exploring cabozantinib (Cabometyx) for the treatment of patients with advanced carcinoid and pancreatic neuroendocrine tumors.































